High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF study

American Journal of Transplantation

Volumn 10, Issue 7, 2010, Pages 1695-1700

  Martinez, F ^a   Kamar, N ^b   Pallet, N ^a   Lang, P ^c   Durrbach, A ^d   Lebranchu, Y ^e   Adem, A ^f   Barbier, S ^g   Cassuto Viguier, E ^h   Glowaki, F ⁱ   Le Meur, Y ^j   Rostaing, L ^b   Legendre, C ^a   Hermine, O ^a   Choukroun, G ^k  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CHU RANGUEIL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITÉ DE TOURS   (France)

^f HÔPITAL TENON   (France)

^g UNIVERSITÉ DE ROUEN   (France)

^h PASTEUR HOSPITAL   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j BREST UNIVERSITY HOSPITAL   (France)

^k UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

more..

Author keywords

Delayed graft function; Epoetin; Ischemiareperfusion; Renal transplantation

Indexed keywords

BASILIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT ERYTHROPOIETIN; TACROLIMUS; CORTICOSTEROID; CREATININE; DRUG DERIVATIVE; HEMOGLOBIN; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; PLATELET DERIVED GROWTH FACTOR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; COLD ISCHEMIA; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJURY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; PERITONEAL DIALYSIS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; VEIN GRAFT DISEASE; AGED; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FRANCE; GRAFT REJECTION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; SAFETY;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, MONOCLONAL; BLOOD PRESSURE; BODY MASS INDEX; CREATININE; DELAYED GRAFT FUNCTION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FRANCE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PLATELET-DERIVED GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RENAL DIALYSIS; SAFETY; TACROLIMUS;

EID: 79958031337     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03142.x     Document Type: Article

References (23)

1. Perico N, Cattaneo D, Sayegh M, Remuzzi G. Delayed graft function in kidney transplantation. Lancet 2004; 364: 1814-1827.
2. Peeters P, Terryn W, Vanholder R, Lameire N. Delayed graft function in renal transplantation. Curr Opin Crit Care 2004; 10: 489-498.
3. Tapiawala S, Tinckam K, Cardella C et al. Delayed graft function and the risk for death with a functioning graft. J Am Soc Nephrol 2009; Nov 19 [Epub ahead of print].
4. Yarlagadda S, Coca S, Formica RJ, Poggio E, Parikh C. Association between delayed graft function and allograft and patient survival: A systematic review and meta-analysis. Nephrol Dial Transplant 2009; 24: 1039-1047.
5. Peeters P, Vanholder R. Therapeutic interventions favorably influencing delayed and slow graft function in kidney transplantation: Mission impossible? Transplantation 2008; 15: S31-S37.
6. Cariou A, Claessens Y, Pène F et al. Early high-dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: A matched control study. Resuscitation 2008; 76: 397-404.
7. Edelstein CL, Shi Y, Schrier RW. Role of caspases in hypoxiainduced necrosis of rat renal proximal tubules. J Am Soc Nephrol 1999; 10: 1940-1949.
8. Pallet N, Bouvier N, Legendre C et al. Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity. Pharmacol Res 2009; Sep 18 [Epub ahead of print].
9. Lee SH, Li C, Lim SW et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol 2005; 25: 64-76.
10. Salahudeen AK, Haider N, Jenkins J et al. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatininduced acute kidney injury. Am J Physiol Renal Physiol 2008; 294: F1354-F1365.
11. Bohlius J, Schmidlin K, Brillant C. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542.
12. Singh A, Szczech L, Tang K et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
13. Halloran P, Hunsicke rL. Delayed graft function: State of the art, November 10-11, 2000. Summit meeting, Scottsdale, Arizona, USA. Am J Transplant 2001; 1: 115-120.
14. Hernández D, Rufino M, González-Posada J et al. Predicting delayed graft function and mortality in kidney transplantation. Transplant Rev (Orlando) 2008; 22: 21-26.
15. Kamar N, Garrigue V, Karras A et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: A randomized, multicenter study. Am J Transplant 2006; 6: 1042-1048.
16. Corwin H, Gettinger A, Pearl R et al. Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 2002; 288: 2827-2835.
17. Sharples E, Patel N, Brown P, Stewart K. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemiareperfusion. J Am Soc Nephrol 2004; 15: 2115-2124.
18. Locatelli F, Aljama P, Bárány P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2): ii1-47.
19. Stüben G, Pöttgen C, Knühmann K et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003; 55: 1358-1362.
20. Van Biesen W, Vanholder R, Veys N, Verbeke F, Lameire N. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005; 79: 367-368.
21. Binbrek A, Rao N, Al Khaja N, Assaqqaf J, Sobel B. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol 2009; 104: 1035-1040.
22. Pfeffer M, Burdmann E, Chen C, Cooper M. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. N Engl JMed 2009; 361: 2019-2032.
23. Newland A, Black C. Tumor progression associated with erythropoiesis-stimulating agents. Ann Pharmacother 2008; 42: 1865-1870.